Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X
Ovid pens deal to offload twice-failed former lead program, positioning [...]
Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling to leave ACTIV-3 future in doubt
Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling [...]
CVS to bring late-stage clinical trials to certain locations in push to serve underrepresented patients
CVS to bring late-stage clinical trials to certain locations in [...]
Boundless Bio lures Berkley from Ionis to support clinical push
Boundless Bio lures Berkley from Ionis to support clinical push [...]
CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase data on C5 inhibitor
CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase [...]
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck’s drug
Bayer ends work on cough med that passed phase 2b [...]
Sanofi ends two phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends two phase 1 cancer assets weeks after axing [...]
Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal
Sanofi ends 2 phase 1 cancer assets weeks after axing [...]
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members [...]
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx
UCB races to regulators after $2.5B rare disease bet delivers [...]